Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Sci Rep ; 10(1): 6079, 2020 04 08.
Article in English | MEDLINE | ID: mdl-32269261

ABSTRACT

The genetic variants of Mannose-Binding Lectin, a vital component of innate immunity have been studied with acute/recurrent vaginal infections ((R)VVI) and presented inconclusive findings. Therefore, a systematic review and meta-analysis of published data were conducted to assess the possible role of these variations in (R)VVI. A comprehensive search was made using PubMed, Web of Science and Google scholar till June 18, 2019. A total of 12 studies met the specified criteria and were included in the analysis. Different comparisons were made on the basis of the outcome of interest that resulted in the filtering of studies for the pooled analysis to find an association using the standard genetic models. Odds ratio (OR) with 95% confidence interval (CI) was chosen as the effect measure for the data synthesis. The trim and fill technique was applied to adjust the publication bias. The meta-analysis revealed the significant association (p < 0.05) of rs1800450 polymorphism with RVVI risk (OR ≥ 3.5) in all the genetic models. The subgroup analysis identified the same association in Caucasian and Mixed ethnicity. Quantitative synthesis based on RVVC showed>3.5 fold risk of disease development accredited to rs1800450. A combined evaluation of Exon1 variants showed no association with (R)VVI. This meta-analysis suggests rs1800450 polymorphism as a genetic predisposing factor for RVVI, but to reinforce, further studies with a larger sample size are warranted.


Subject(s)
Mannose-Binding Lectin/genetics , Polymorphism, Single Nucleotide , Vulvovaginitis/genetics , Adult , Female , Humans , Middle Aged , Recurrence , Vulvovaginitis/pathology
2.
J Investig Med High Impact Case Rep ; 7: 2324709619842901, 2019.
Article in English | MEDLINE | ID: mdl-31043089

ABSTRACT

We describe a case of acute erosive vulvovaginitis accompanying Borrelia burgdorferi infection. The patient is a 57-year-old woman previously diagnosed with Lyme disease who presented with a painful erosive genital lesion. At the time of the outbreak, she was being treated with oral antibiotics, and she tested serologically positive for B burgdorferi and serologically negative for syphilis. Histological examination of biopsy tissue from the lesion was not characteristic of dermatopathological patterns typical of erosive vulvar conditions. Dieterle-stained biopsy sections revealed visible spirochetes throughout the stratum spinosum and stratum basale, and anti- B burgdorferi immunostaining was positive. Motile spirochetes were observed by darkfield microscopy and cultured in Barbour-Stoner-Kelly-complete medium inoculated with skin scrapings from the lesion. Cultured spirochetes were identified genetically as B burgdorferi sensu stricto by polymerase chain reaction, while polymerase chain reaction amplification of treponemal gene targets was negative. The condition resolved after treatment with additional systemic antibiotic therapy and topical antibiotics. In cases of genital ulceration that have no identifiable etiology, the possibility of B burgdorferi spirochetal infection should be considered.


Subject(s)
Borrelia burgdorferi/isolation & purification , Lyme Disease/complications , Vulvovaginitis/etiology , Vulvovaginitis/microbiology , Biopsy , DNA, Bacterial/analysis , Female , Humans , Lyme Disease/pathology , Middle Aged , Polymerase Chain Reaction , Vulvovaginitis/pathology
3.
J Int Med Res ; 47(6): 2626-2636, 2019 Jun.
Article in English | MEDLINE | ID: mdl-31088247

ABSTRACT

OBJECTIVE: To evaluate the acceptability, tolerability, and effects on vulvovaginitis symptoms and signs of a non-soap, herbal-based intimate solution (Zelesse®). METHODS: We conducted a prospective, observational, multicenter study including adult women with symptoms and signs of vulvovaginitis with various etiologies, including candidiasis, trichomoniasis, bacterial vaginosis, and atrophic and irritative vaginitis. The presence and intensity of signs (edema, erythema, vaginal discharge) and symptoms (pruritus) of vulvovaginitis were evaluated before and after 5-15 days of daily use of Zelesse® alone or as a coadjuvant in antimicrobial therapy. Variables following a normal distribution and categorical variables were analyzed using the Student t-test and chi-square or Fisher's exact test, respectively. RESULTS: A total 137 women were enrolled in the study; 87 (63.5%) women received concomitant antimicrobials and 50 (36.5%) used Zelesse® only. Global symptom scores and frequency of patients with vulvovaginitis signs and symptoms, and their mean intensity, decreased after treatment in both patient groups. Vaginal pH and (in the Zelesse®-only group) vaginal flora remained unaltered. The product was safe, well tolerated, and highly accepted by patients. CONCLUSIONS: Zelesse®, the non-soap herbal-based solution in this study, may represent a safe and effective option for symptomatic relief of vulvovaginitis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Phytotherapy , Severity of Illness Index , Solutions/administration & dosage , Vulvovaginitis/drug therapy , Vulvovaginitis/pathology , Adult , Female , Follow-Up Studies , Humans , Hygiene , Male , Maximum Tolerated Dose , Prognosis , Prospective Studies , Spain/epidemiology , Vulvovaginitis/epidemiology
4.
J Low Genit Tract Dis ; 23(2): 176-181, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30907778

ABSTRACT

OBJECTIVES: Wet mount microscopy (WMM) is an ancillary test in the diagnosis of vulvovaginitis. However, there are little data about the impact of the sampling site. Our main objective was to determine the agreement between samples collected from different vaginal sites. MATERIALS AND METHODS: Five vaginal samples (one from each of the fornices and one from the lower third) were collected from 50 consecutive women and evaluated using phase-contrast WMM, including the following: lactobacillary grade, presence of other bacteria, clue cells, inflammation, and atrophy. Global percentage of agreement, κ index [poor (<0), slight (0.01-0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80), and almost perfect (0.81-1)], sensitivity and negative predictive value were calculated. RESULTS: Global percentage of agreement was high for all individual parameters (>75%), but low for the final diagnosis (57%). Agreement rate was substantial or almost perfect for the evaluation of normal versus abnormal flora, substantial for the presence of absence of bacteria other than lactobacilli and for the presence of clue cells, and moderate to almost perfect for the presence of dysbiosis and cytolysis. Agreement rates were worse for inflammation, atrophy, and the presence of Candida. The lower third of the vagina had the highest sensitivity for Candida (0.6, 95% CI = 0.41-0.86) and bacterial vaginosis (0.92, 95% CI = 0.73-1.00), whereas the anterior fornix performed better for cytolytic vaginosis (0.75, 95% CI = 0.43-0.93). CONCLUSIONS: There is some variation in the results according to the sampling site, which may be overcome by collecting 2 samples (anterior fornix and lower third of the vagina).


Subject(s)
Microscopy, Phase-Contrast/methods , Specimen Handling/methods , Vagina/pathology , Vulvovaginitis/diagnosis , Vulvovaginitis/pathology , Adult , Female , Humans , Middle Aged , Predictive Value of Tests , Sensitivity and Specificity , Young Adult
5.
Benef Microbes ; 10(8): 867-872, 2019 Dec 09.
Article in English | MEDLINE | ID: mdl-31965832

ABSTRACT

Disruption of vaginal microbiota equilibrium promotes infectious clinical syndromes with annoying symptoms, such as vaginal discharge, odour, irritation, pruritus, and vulvar burning. Although identifying and eradicating the pathogen involved has been the standard of care, regional microbiota restoration with probiotics has been gaining ground in recent years. This study aimed to assess the effectiveness of topical Bacillus coagulans treatment for patients exhibiting vaginal discomfort symptoms. A clinical trial was conducted on the use of a topical B. coagulans regimen among reproductive-age women (n=70) with vaginal discomfort symptoms. We assessed their symptoms using a questionnaire, measured vaginal pH, and performed vaginal swabs for microscopy and cultivation. Over the next 4 days, patients received B. coagulans vaginal douches and suppositories with appropriate antibiotic treatment being added on the fourth day based on vaginal swab results. Patients returned 16 days later to fill out in the questionnaire again. The Wilcoxon signed-ranked test was then used to assess differences in symptomatology and pH between appointments. A reduction in vaginal pH was reported between the first and second visit (P<0.001). The probiotic regimen exerted a beneficial effect in all vaginal manifestations: vulvovaginal itching, burning sensation, vaginal irritation, and vaginal discharge (P<0.001 for all symptoms). Additionally, three out of the four symptoms were alleviated to a greater extent during the first four days of exclusive probiotic use than during the second phase (P=0.007, P=0.004, and P=0.033). Our sample provided significant results regarding the benefits of B. coagulans for vaginal discomfort. We postulate that the greatest symptom improvement was achieved within the first 4 days of exclusive probiotic use, before the addition of antibiotics. This study agrees with the increasing literature on the contribution of probiotics toward vaginitis treatment.


Subject(s)
Probiotics/administration & dosage , Probiotics/pharmacology , Vagina/drug effects , Vulvovaginitis/therapy , Administration, Intravaginal , Adolescent , Adult , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/pharmacology , Bacillus coagulans , Female , Humans , Hydrogen-Ion Concentration , Middle Aged , Treatment Outcome , Vagina/chemistry , Vagina/microbiology , Vagina/pathology , Vulvovaginitis/microbiology , Vulvovaginitis/pathology , Young Adult
6.
Assay Drug Dev Technol ; 16(3): 141-149, 2018 04.
Article in English | MEDLINE | ID: mdl-29658789

ABSTRACT

The antifungal effects of 2-phenylethanol are clearly visible through its intervention in Candida morphogenesis. Chronic and recurrent vulvovaginitis, however, does not respond to this standard experimental therapy; therefore, the study presented in this article investigated the effect of common antifungal drugs (amphotericin B [AMB], fluconazole [FLU], and itraconazole [ITC]), in combination with 2-phenylethanol, on the Candida species isolated from cases of chronic and recurrent vulvovaginitis, thereby allowing the recommendation of a more appropriate treatment option. Forty isolates from patients with chronic and recurrent vaginal candidiasis were investigated in this experimental study. The specimens were examined by direct microscopy, culturing, and PCR to identify the species. The antifungal effects of 2-phenylethanol and conventional drugs, both alone and in combination, were determined in duplicate. Finally, the findings were analyzed. In this study, 40 strains of Candida species were identified, whose agents were Candida albicans (95%) and Candida africana (5%). After 48 h, the minimum inhibitory concentration (MIC) range of the 2-phenylethanol was 800-3,200 µg/mL. Also, in the final study on the MIC levels of common antifungal drugs, AMB (0.42 µg/mL) had the lowest MIC, FLU (40.51 µg/mL) had the highest MIC, and the combination of ITC and 2-phenylethanol had the lowest fractional inhibitory concentration index (FICI) of any of the combinations (FICI range, 0.26-1.03). Combining FLU and ITC with 2-phenylethanol can effectively increase their antifungal effect.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Candida/drug effects , Fluconazole/pharmacology , Itraconazole/pharmacology , Phenylethyl Alcohol/pharmacology , Vulvovaginitis/microbiology , Adult , Candida/isolation & purification , Chronic Disease , Dose-Response Relationship, Drug , Female , Humans , Middle Aged , Vulvovaginitis/drug therapy , Vulvovaginitis/pathology
8.
Gynecol Endocrinol ; 31(4): 317-21, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25559048

ABSTRACT

OBJECTIVES: Exploratory pilot study to determine the correlation between postmenopausal vulvovaginal symptoms and vaginal cytokine levels. METHODS: Postmenopausal women (n = 34) not using menopausal hormone therapy and presenting with or without symptoms of vulvovaginal irritation were screened. Each participant underwent a vaginal examination and screening for vaginitis. A cervicovaginal lavage (CVL) with sterile saline and a peripheral blood sample were obtained. Main outcome measures were assessed by Luminex® X-map method on the Bio-Plex® platform. Main outcome measures were cervicovaginal and serum interleukin (IL)-4, IL-5, IL-10, IL-12, IL-13, TNF-α, GM-CSF, MIP-1-alpha and RANTES level. Cervicovaginal cytokines were adjusted to total protein concentration [pg/mcg protein]. RESULTS: Twenty-six postmenopausal women were enrolled (symptomatic: n = 15; asymptomatic: n = 11). There were no significant differences between groups: age, age at menopause, vaginal pH and all CVL and serum cytokines (IL-4, IL-5, IL-10, IL-12, IL-13, TNF-α, GM-CSF, MIP-1-alpha and RANTES). GM-CSF was the most abundant vaginal cytokine (symptomatic: 146.5 ± 165.6 pg/mcg protein; asymptomatic: 146.0 ± 173.5 pg/mcg protein; p = 0.99). CONCLUSIONS: Postmenopausal vulvovaginal symptoms did not correlate with vaginal inflammatory marker. There was no difference in serum or CVL cytokines between symptomatic and asymptomatic postmenopasual women. Vaginal symptoms after menopause are not related to the vaginal cytokine changes associated with loss of estrogen.


Subject(s)
Aging , Cytokines/metabolism , Mucous Membrane/metabolism , Vagina/metabolism , Vulvovaginitis/metabolism , Atrophy , Biomarkers/blood , Biomarkers/metabolism , Cross-Sectional Studies , Cytokines/blood , Female , Humans , Middle Aged , Mucous Membrane/immunology , Mucous Membrane/pathology , Pilot Projects , Postmenopause , Severity of Illness Index , Vagina/immunology , Vagina/pathology , Vaginal Douching , Vulvovaginitis/immunology , Vulvovaginitis/pathology , Vulvovaginitis/physiopathology
9.
Menopause ; 22(8): 845-9, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25608269

ABSTRACT

OBJECTIVE: Microablative fractional CO2 laser has been proven to determine tissue remodeling with neoformation of collagen and elastic fibers on atrophic skin. The aim of our study is to evaluate the effects of microablative fractional CO2 laser on postmenopausal women with vulvovaginal atrophy using an ex vivo model. METHODS: This is a prospective ex vivo cohort trial. Consecutive postmenopausal women with vulvovaginal atrophy managed with pelvic organ prolapse surgical operation were enrolled. After fascial plication, the redundant vaginal edge on one side was treated with CO2 laser (SmartXide2; DEKA Laser, Florence, Italy). Five different CO2 laser setup protocols were tested. The contralateral part of the vaginal wall was always used as control. Excessive vagina was trimmed and sent for histological evaluation to compare treated and nontreated tissues. Microscopic and ultrastructural aspects of the collagenic and elastic components of the matrix were studied, and a specific image analysis with computerized morphometry was performed. We also considered the fine cytological aspects of connective tissue proper cells, particularly fibroblasts. RESULTS: During the study period, five women were enrolled, and 10 vaginal specimens were finally retrieved. Four different settings of CO2 laser were compared. Protocols were tested twice each to confirm histological findings. Treatment protocols were compared according to histological findings, particularly in maximal depth and connective changes achieved. All procedures were uneventful for participants. CONCLUSIONS: This study shows that microablative fractional CO2 laser can produce a remodeling of vaginal connective tissue without causing damage to surrounding tissue.


Subject(s)
Atrophic Vaginitis/surgery , Laser Therapy/methods , Lasers, Gas/therapeutic use , Postmenopause , Vulvovaginitis/surgery , Aged , Atrophic Vaginitis/pathology , Female , Humans , Middle Aged , Pelvic Organ Prolapse/surgery , Prospective Studies , Vagina/pathology , Vagina/surgery , Vulvovaginitis/pathology
10.
J Low Genit Tract Dis ; 19(1): e6-9, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24769650

ABSTRACT

Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.


Subject(s)
Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Pyoderma Gangrenosum/chemically induced , Pyoderma Gangrenosum/pathology , Vulvovaginitis/chemically induced , Vulvovaginitis/pathology , Female , Humans , Middle Aged , Rituximab
11.
An Bras Dermatol ; 89(5): 843-4, 2014.
Article in English | MEDLINE | ID: mdl-25184936

ABSTRACT

Vulvovaginal-gingival syndrome is characterized by erosions and desquamation of the vulva, vagina, and gingiva. We reported a case of a 32-year-old woman presenting with an 8-year history of damage to the vulval and perianal anatomy and limitation of mouth opening. The patient's symptoms were relieved after treatment with topical tacrolimus cream.


Subject(s)
Gingivitis/pathology , Lichen Planus/pathology , Vulvovaginitis/pathology , Adult , Biopsy , Female , Humans , Keratosis/pathology , Syndrome
12.
An. bras. dermatol ; 89(5): 843-844, Sep-Oct/2014. graf
Article in English | LILACS | ID: lil-720806

ABSTRACT

Vulvovaginal-gingival syndrome is characterized by erosions and desquamation of the vulva, vagina, and gingiva. We reported a case of a 32-year-old woman presenting with an 8-year history of damage to the vulval and perianal anatomy and limitation of mouth opening. The patient's symptoms were relieved after treatment with topical tacrolimus cream.


Subject(s)
Humans , Female , Adult , Vulvovaginitis/pathology , Gingivitis/pathology , Lichen Planus/pathology , Syndrome , Biopsy , Keratosis/pathology
13.
Postgrad Med J ; 90(1059): 8-12, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24191064

ABSTRACT

OBJECTIVE: To compare vaginal culture results between prepubertal girls with and without vulvovaginitis, and obtain an overview of the most commonly encountered microbes. DESIGN: Prospective descriptive study. SETTING: Outpatient clinic of Vilnius University Hospital Santariskiu Klinikos during September 2011-December 2012. PATIENTS: 115 prepubertal girls with vulvovaginitis symptoms and additionally 20 age-matched asymptomatic girls. METHODS: Each girl had a vaginal smear carried out using a sterile swab from the introitus or lower third of the vagina. All samples were referred to the microbiology laboratory where standard microbiological diagnostic procedures were performed. RESULTS: Positive microbiological findings were seen in all 115 (100%) symptomatic girls and in 12 (60%) control group girls (p<0.001). Pathogenic bacteria were found only in symptomatic girls. Statistically significant differences in bacteria culture results (pure or mixed) and growth of isolated bacteria colonies between patients versus healthy girls were found (p<0.05). The dominant bacteria in the target group, accounting for 66% of all isolated microbes, were Escherichia coli, Enterococcus faecalis, Staphylococcus coagulase negative, Streptococcus α haemolyticus and A group Streptococcus ß haemolyticus. The bacteria of faecal origin were isolated from 61 (53%) girls with vulvovaginitis and from 5 (25%) girls without vaginal inflammation (p<0.05). Instances of Candida species were extremely rare (2.6%). CONCLUSIONS: Positive microbiological findings, mixed bacteria cultures and a high growth of bacteria colonies are found significantly more often in girls with vulvovaginitis. The main causative premenarchal vulvovaginitis agents are faecal in origin.


Subject(s)
Vagina/microbiology , Vulvovaginitis/microbiology , Anti-Bacterial Agents/adverse effects , Child, Preschool , Enterococcus faecalis/isolation & purification , Escherichia coli/isolation & purification , Female , Humans , Hygiene , Infant , Lithuania , Obesity/complications , Prospective Studies , Staphylococcus/isolation & purification , Streptococcus pyogenes/isolation & purification , Vagina/pathology , Vulvovaginitis/etiology , Vulvovaginitis/pathology
14.
Transbound Emerg Dis ; 61(5): 443-8, 2014 Oct.
Article in English | MEDLINE | ID: mdl-23289592

ABSTRACT

It is known that lumpy skin disease virus (LSDV) can be shed in bull semen following infection and also that artificial insemination (AI) poses a biosecurity risk. However, it is not known whether the use of LSDV infected semen in AI poses a biosecurity risk. The aim of this study was to investigate whether LSDV, transmitted through semen, can infect cows and their embryos. Two controlled trials were performed simultaneously. Eleven young beef heifers, naïve to LSDV, were synchronized using an OvSynch protocol and inseminated on Day 0 with fresh semen spiked with a field strain of LSDV on day 0. Six of the heifers were superovulated on Day 1 using pregnant mare serum gonadotropin, and embryos were flushed from these heifers on Day 6. Blood and serum samples were collected from Day 4 until Day 27 to determine the presence of LSDV by PCR and virus isolation, and the presence of antibodies against LSDV by SNT. The first clinical signs of LSD were noticed on Day 10, followed by severe generalized LSD in three heifers and mild LSD in two more heifers. Two heifers were humanely euthanized due to severe unresponsive stranguria. LSDV was detected by PCR, virus isolation or electron microscopy in blood, embryos and organs of experimentally infected animals; and eight heifers had seroconverted by Day 27. Two control animals were not affected. This is the first report of experimental seminal transmission of LSDV in cattle.


Subject(s)
Insemination, Artificial/veterinary , Lumpy Skin Disease/transmission , Lumpy skin disease virus/isolation & purification , Semen/virology , Animals , Cattle , Endometritis/pathology , Endometritis/veterinary , Endometritis/virology , Female , Insemination, Artificial/adverse effects , Lumpy Skin Disease/pathology , Polymerase Chain Reaction/veterinary , Pregnancy , Vulvovaginitis/pathology , Vulvovaginitis/veterinary , Vulvovaginitis/virology
15.
J Formos Med Assoc ; 111(7): 392-6, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22817817

ABSTRACT

BACKGROUND/PURPOSE: Vulvovaginitisis the most common gynecological problem of childhood. The aim of the study was to determine and compare clinical and microbiological features of vulvovaginitis in prepubertal and adolescent girls. METHODS: In this retrospective study, the records of patients who were diagnosed with vulvovaginitis between January 2005 and December 2010 in the pediatric outpatient clinic at Fatih University Hospital were retrieved. Information regarding age, symptoms, history of antibiotic use within 1 month prior to presentation, findings on urinalysis, serum antistreptolysin-O levels, and results of urine/vaginal cultures was collected. RESULTS: The records of 112 patients were evaluated, 72 of which were prepubertal (64.2%) and 40 were pubertal (35.7%) at the time of diagnosis. Thirty-eight prepubertal patients (52.7%) had a positive result on vaginal culture, the most commonly encountered microorganism being group A beta-hemolytic streptococcus (15.2%). Culture positivity rate in the pubertal group was 47.5% (19 patients), with Candida albicans being the most frequently isolated microorganism (27.5%). CONCLUSION: The etiopathogenesis and culture results differ between prepubertal and adolescent girls with vulvovaginitis, which should be taken into consideration in the treatment approach of this disorder.


Subject(s)
Vulvovaginitis/microbiology , Adolescent , Age Factors , Candidiasis, Vulvovaginal/microbiology , Candidiasis, Vulvovaginal/pathology , Child , Child, Preschool , Escherichia coli Infections/microbiology , Escherichia coli Infections/pathology , Female , Haemophilus Infections/microbiology , Haemophilus Infections/pathology , Haemophilus influenzae , Humans , Puberty , Retrospective Studies , Streptococcal Infections/microbiology , Streptococcal Infections/pathology , Vagina/microbiology , Vagina/pathology , Vulva/microbiology , Vulva/pathology , Vulvovaginitis/pathology
16.
J Low Genit Tract Dis ; 16(1): 24-9, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21964206

ABSTRACT

OBJECTIVE: This study aimed to examine differences in symptoms and diagnoses between women 50 years and younger and women older than 50 years who have chronic vulvovaginal complaints. METHODS: New patients of the Drexel University Vaginitis Center with chronic vulvovaginal complaints were eligible. Participants underwent a standardized medical evaluation and completed detailed questionnaires. Data were analyzed using the t test, χ test, and the Fisher exact test. RESULTS: Subjects were 469 women aged 18 to 79 years. Subjects 50 years and younger (group A) were more likely to complain of vaginal itching and were less likely to complain of burning, irritation, or soreness (p ≤ .05 for all). Subjects older than 50 years (group B) were more likely to be diagnosed with atrophic vaginitis (p = .000), desquamative inflammatory vaginitis (DIV; p = .001), lichen planus (LP; p = .000), and lichen sclerosus (p = .000). Diagnosis of LS, LP, or DIV was associated with increased likelihood of multiparity and decreased likelihood of a history of systemic estrogen use. CONCLUSIONS: Postmenopausal women are more likely than premenopausal women to be diagnosed with DIV, LP, or LS. Both childbirth and estrogen nonuse were associated with the occurrence of these latter 3 conditions.


Subject(s)
Vulvovaginitis/diagnosis , Vulvovaginitis/pathology , Adolescent , Adult , Age Factors , Aged , Chronic Disease , Cohort Studies , Female , Humans , Inflammation/etiology , Inflammation/pathology , Lichen Planus/diagnosis , Lichen Planus/pathology , Lichen Sclerosus et Atrophicus/diagnosis , Lichen Sclerosus et Atrophicus/pathology , Middle Aged , Postmenopause , Premenopause , Prospective Studies , Young Adult
17.
Prog. obstet. ginecol. (Ed. impr.) ; 54(11): 568-574, nov. 2011. tab, ilus
Article in Spanish | IBECS | ID: ibc-91172

ABSTRACT

Objetivos. Valorar la utilidad de la determinación del pH vaginal en el primer control del embarazo para el diagnóstico de vulvovaginitis y su relación con la patología obstétrica. Material y métodos. Hemos realizado el estudio en 200 embarazadas de bajo riesgo. Efectuamos el pH vaginal en el primer control del embarazo a las gestantes. Independientemente de su sintomatología, tomamos cultivo de exudado vaginal (CEV) a 103 pacientes; a las otras 97 pacientes lo realizamos si tenían síntomas y/o un pH > 4,5. Solo pusimos tratamiento si eran sintomáticas. Seguimos la evolución de sus embarazos para valorar su patología obstétrica y sus partos. Resultados. La media de pH en la muestra fue 4,41 (4,04–4,78). Encontramos una asociación estadísticamente muy significativa entre la elevación de pH vaginal superior a 4,5 y el aislamiento mediante cultivo de Gardnerella vaginalis (G. vaginalis) (p<0,000), con un OR de 35,15 (4,67–730,39). La mayoría de los cultivos fueron normales, y los gérmenes aislados por orden de frecuencia fueron: Candida albicans (C. albicans) (17,5%), G. vaginalis (7,8%) y Streptococcus agalactiae (7,8%), siendo más del 85% de las gestantes portadoras asintomáticas. La patología obstétrica registrada en nuestra muestra ha sido: amenazas de parto prematuro (2%), roturas prematuras de membranas (2%), partos pretérmino (4,5%) y abortos espontáneos (6%). Conclusiones. El pH vaginal puede ser una buena prueba de cribado para el diagnóstico de vaginosis bacterianas. El germen más prevalente en nuestra muestra ha sido C. albicans siendo la mayoría de gestantes portadoras asintomáticas. No hemos encontrado relación entre la patología obstétrica registrada y los gérmenes aislados en los cultivos de exudado vaginal (AU)


Objective. To assess the usefulness of vaginal pH determination in the first prenatal visit in the diagnosis of vulvovaginitis and its association with obstetric abnormalities. Material and methods. We determined vaginal pH in the first prenatal visit in 200 low-risk pregnancies. In 103 women, vaginal secretions were cultured, independently of their symptoms. In the remaining 97 women, culture was performed only if symptoms were present and/or pH was >4.5. Treatment was prescribed in symptomatic women only. The pregnancies were followed up to evaluate obstetric abnormalities and data on deliveries. Results. The mean pH in the study sample was 4.41 (4.04–4.78). We found a statistically significant association (P<.000) between an increase in vaginal pH over 4.5 and isolation through culture of Gardnerella vaginalis (G. vaginalis), with an OR of 35.15 (4.67–730.39). Most cultures were normal. In order of frequency, the identified microorganisms were Candida albicans (C. albicans) (17.5%), G. vaginalis (7.8%) and Streptococcus agalactiae (7.8%). More than 85% of the carriers were asymptomatic. Obstetric pathology in our sample consisted of preterm labor (2%), premature rupture of membranes (2%), preterm delivery (4.5%) and miscarriage (6%). Conclusions. Vaginal pH determination might be an effective screening test for the diagnosis of bacterial vaginosis. The most prevalent microorganism in our sample was C. albicans and most carriers were asymptomatic. We found no relationship between obstetric pathology and the microorganisms isolated in cultures of vaginal secretions (AU)


Subject(s)
Female , Pregnancy , Adult , Humans , Vulvovaginitis/diagnosis , Gardnerella vaginalis/isolation & purification , Candida albicans/isolation & purification , Streptococcus agalactiae/isolation & purification , Vulvovaginitis/pathology , Mass Screening/methods
18.
Obstet Gynecol ; 117(4): 850-855, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21422855

ABSTRACT

OBJECTIVE: Desquamative inflammatory vaginitis is a clinical syndrome frequently unrecognized, characterized by vaginal rash and purulent discharge. We describe patient outcomes and treatment at follow-up in a case series of 98 women diagnosed with this syndrome. METHODS: We performed a chart review of 130 patients diagnosed with desquamative inflammatory vaginitis between 1996 and 2007 in a referral university-based vaginitis clinic. Clinical findings, laboratory findings, and treatment were documented during the first 12 months and at 2 and 4 years. RESULTS: Of the 98 patients reviewed, 97 were white; mean age was 48.6 years (plus or minus 10.2 years), and 50% were postmenopausal. All patients were symptomatic with vaginal inflammation and 72% had vestibular findings. Treatment with topical 2% clindamycin (54%) or 10% hydrocortisone (46%) dramatically relieved symptoms within 3 weeks (median) in 86% of patients. Treatment was discontinued (median 8 weeks) in 53 patients experiencing clinical remission accompanied by normal wet mount appearance; however, 17 (32%) relapsed within 6 weeks. At 1 year, cure was achieved in 25 patients (26%), 57 (58%) were asymptomatic but remained dependent on maintenance treatment, and 16 (16%) were partially controlled only. A favorable initial response to therapy was associated with positive clinical prognosis by 20 weeks of follow-up (P=.01). CONCLUSION: Desquamative inflammatory vaginitis is a chronic inflammatory process involving both vagina and vestibule, occurring almost exclusively in white women, that responds well to topical anti-inflammatory therapy, although long-term maintenance therapy frequently is required. LEVEL OF EVIDENCE: III.


Subject(s)
Clindamycin/therapeutic use , Hydrocortisone/therapeutic use , Vulvovaginitis/drug therapy , Vulvovaginitis/pathology , Administration, Topical , Adult , Age Factors , Cohort Studies , Confidence Intervals , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Kaplan-Meier Estimate , Middle Aged , Prognosis , Recurrence , Retrospective Studies , Risk Assessment , Severity of Illness Index , Treatment Outcome , Vulvovaginitis/diagnosis
19.
Minerva Ginecol ; 62(4): 287-91, 2010 Aug.
Article in Italian | MEDLINE | ID: mdl-20827246

ABSTRACT

It is sometimes difficult to treat vulvovaginal itching and dryness, which represent frustrating symptoms for both patients and doctors. In case that the etiological agent is Candida albicans, effective antimycotic therapies are available; however, itching is often caused by aspecific allergic-irritative factors, which are difficult to be defined. In these cases, patients are invited to limit local irritative factors; nevertheless, this advice is not always taken and sometimes it turns out to be insufficient. Besides behavioral suggestions, a therapeutic support would be useful; medical doctors habitually prescribe local symptomatic treatments which, however, do not target numerous causes of irritative vulvovaginal symptomatology, though they are formulated for vulvovaginal application. If there is estrogenic deficit, the best therapeutic approach is based on topical estrogenic therapy, which is sometimes ineffective on vulvar symptoms. Frequently, it is necessary to choose a complementary therapeutic tool for vaginal application in order to alleviate itching, burning, erythema, dryness. The aim of this study was to evaluate the efficacy of an innovative anhydrous lipogel containing vitamin E and boswellic acids. Results of this study, performed on 34-58-year-old patients, confirmed the efficacy of the lipogel on irritative vulvovaginal symptoms. In postmenopausal women, the lipogel is a useful synergistic complement to topical hormonal therapy.


Subject(s)
Estrogens/administration & dosage , Hydrogel, Polyethylene Glycol Dimethacrylate/administration & dosage , Lipids/administration & dosage , Vulvovaginitis/drug therapy , Administration, Intravaginal , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antifungal Agents/administration & dosage , Atrophy/drug therapy , Candidiasis, Vulvovaginal/drug therapy , Candidiasis, Vulvovaginal/pathology , Clinical Trials as Topic , Drug Combinations , Drug Therapy, Combination , Evidence-Based Medicine , Female , Humans , Ointments/administration & dosage , Pruritus/drug therapy , Severity of Illness Index , Treatment Failure , Treatment Outcome , Triterpenes/administration & dosage , Vitamin E/administration & dosage , Vulvovaginitis/pathology
20.
Vet Rec ; 165(11): 319-22, 2009 Sep 12.
Article in English | MEDLINE | ID: mdl-19749209

ABSTRACT

A syndrome in which white foci and granulopustular lesions appeared on the vaginal mucous membranes of Holstein cows in several dairy herds in Israel is described. During clinical and diagnostic investigations, Mycoplasma bovigenitalium was isolated from 11 of 20 clinical cases. Vaginal swabs taken from the same cows yielded three isolates of Mycoplasma canadense, which were all associated with the M bovigenitalium infection. Two isolates of small, round, non-enveloped viral particles were approximately 25 nm in diameter and characteristic of enteroviruses on negative-staining electron microscopy.


Subject(s)
Cattle Diseases/microbiology , Mycoplasma Infections/veterinary , Mycoplasma/isolation & purification , Vulvovaginitis/veterinary , Aborted Fetus/microbiology , Aborted Fetus/pathology , Abortion, Veterinary , Animals , Biopsy , Cattle , Cattle Diseases/epidemiology , Cattle Diseases/pathology , Dairying , Female , Israel/epidemiology , Mycoplasma/classification , Mycoplasma Infections/epidemiology , Mycoplasma Infections/pathology , Vulvovaginitis/microbiology , Vulvovaginitis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...